Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X:
“EMPRESS 15 days of neoadj giredestrant vs. tamoxifen (without GnRH).
51% Ki-67 decline with tam, 73% giredestrant.
Complete cell cycle arrest much higher with giredestrant.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
